Directorio

We are doing this study to learn how normal, healthy aging affects attention, perception, memory, and decision-making abilities. We also want to know which regions of the brain contribute to these abilities.

We are doing this study to compare the effectiveness of atezolizumab + a multi-kinase inhibitor (either cabozantinib or lenvatinib) versus a multi-kinase inhibitor alone.

We are doing this study to learn more about the differences in the muscle and blood of people that have Peripheral Arterial Disease (PAD).

We are doing this study to compare the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib. We want to find out if adding gilteritinib to the usual treatment is beneficial for people with acute myeloid leukemia (AML).

We are doing this study to compare different experimental drug regimens to the usual treatment (cytarabine and daunorubicin) for acute myeloid leukemia (AML). We want to find out which options have the best outcomes. The different drug combinations we will be testing against the usual treatment are:

• daunorubicin and cytarabine liposome
• cytarabine and daunorubicin with venetoclax
• azacitidine and venetoclax
• daunorubicin and cytarabine liposome with venetoclax

We are doing this study to see if blood and bone marrow samples can be tested in a timely manner that allows for the detection of certain markers that could guide cancer treatment.

We are doing this study to better understand nonalcoholic fatty liver disease in people with HIV. We want to find out what are the most accurate, non-invasive diagnostic tests to detect scarring in the liver for people who have HIV. At this time, we do not have a good understanding of the following characteristics of steatotic liver disease in people with HIV:

• Causes of the disease
• Risk factors
• The most accurate, non-invasive tests to measure liver scarring
• How the disease progresses
• Treatment options

We are doing this study to find out if an investigational vaccine (HydroVax-005 CHIKV - the study vaccine) is a safe and effective option to protect against chikungunya virus. Chikungunya virus is spread by mosquitos that are most common in Africa, Asia, and India. Infection with the virus can cause serious disease in older adults, children, and people with weaker immune systems.